403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Bridgebio To Participate In September Investor Conferences
(MENAFN- GlobeNewsWire - Nasdaq) PALO ALTO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the“Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today announced that members of its management team will participate in fireside chats at the following healthcare investor conferences:
To access the live webcast of BridgeBio's presentations, please visit the“Events and Presentations” page within the Investors section of the BridgeBio website at About BridgeBio Pharma, Inc.
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com LinkedIn X Facebook Instagram YouTube TikTok
- 21st Annual Wells Fargo Healthcare Conference, Boston, MA: Wednesday, September 9 at 1:30 pm EDT 2026 Cantor Global Healthcare Conference, New York, NY: Thursday, September 10 at 9:10 am EDT Morgan Stanley 24th Annual Global Healthcare Conference, New York, NY: Tuesday, September 15 at 10:00 am EDT Bernstein Insights Healthcare Leaders and Disruptors 2026, New York, NY: Wednesday, September 23 at 9:40am EDT
To access the live webcast of BridgeBio's presentations, please visit the“Events and Presentations” page within the Investors section of the BridgeBio website at About BridgeBio Pharma, Inc.
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com LinkedIn X Facebook Instagram YouTube TikTok
BridgeBio Media Contact:
Kaitlyn Reilly, Director, Communications
...
(650)-789-8220
BridgeBio Investor Contact:
Kristen Kelleher, Director, Investor Relations
...
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment